Table 4. Clinical trials of first-line regimens containing platinum agents reported in the literature from 2000.
| Group | Reference | Regimen | N | RR | MST (m) | 1 yeara | 2 yearb |
|---|---|---|---|---|---|---|---|
| Doublet | Briasoulis et al (2000) | Carbo–P | 77 | 38.7% | 13.0 | NA | NA |
| Voog et al (2000) | Cis–E | 22 | 32% | 8.0 | NA | NA | |
| Greco et al (2000a) | Cis–D | 26 | 26% | 8.0 | 40% | 28% | |
| Carbo–D | 47 | 22% | 8.0 | 33% | 28% | ||
| Dowell et al (2001) | Carbo–E | 17 | 19% | 8.3 | 26% | NA | |
| Saghatchian et al (2001) | Cis–E → Cis–E–B–I | 30 | 40% | 9.4 | NA | 28% | |
| Cis–F | 18 | 44% | 16.1 | NA | 39% | ||
| Culine et al (2002b) | Dx–Cy⇔Cis–E | 82 | 39% | 10.0 | NA | NA | |
| Culine et al (2003) | Cis–G | 39 | 55% | 8.0 | NA | NA | |
| Cis–Ir | 40 | 38% | 6.0 | NA | NA | ||
| Park et al (2004) | Cis–P | 37 | 42% | 11.0 | 38% | 11% | |
| El-Rayes et al (2005) | Carbo–P | 22 | 23% | 6.5 | 27% | NA | |
| Pittman et al (2006) | Carbo–G | 51 | 30.5% | 7.8 | 26% | 12% | |
| Briasoulis et al (2008a) | Ox–Ir | 47 | 13% | 9.5 | 40% | NA | |
| Pentheroudakis et al (2008) | Carbo–D | 47 | 32% | 16.2 | NA | NA | |
| This study | Carbo–Ir | 45 | 41.9% | 12.2 | 44% | 27% | |
| Triplet or more | Parnis et al (2000) | Cis–F–Ep | 43 | 23% | 5.8 | NA | NA |
| Greco et al (2000b) | Carb–P–E | 71 | 48% | 11.0 | 48% | 20% | |
| Guardiola et al (2001) | Cis–Dx–Cy | 22 | 50% | 10.7 | NA | NA | |
| Macdonald et al (2002) | Cis–F–Mit | 31 | 27% | 7.7 | 28% | 10% | |
| Greco et al (2002) | Carbo–G–P | 113 | 25% | 9.0 | 42% | 23% | |
| Balaña et al (2003) | Cis–G–E | 30 | 36.6% | 7.2 | 26% | NA | |
| Piga et al (2004) | Carbo–Dx–E | 102 | 26.5% | 9.0 | 35.2% | 18.1% | |
| Greco et al (2004) | Carbo–P–E → G–Ir | 111 | 33% | 9.1 | 35% | 16% | |
| Palmeri et al (2006) | Cis–G–P | 33 | 48.5% | 9.6 | NA | NA | |
| Cis–G–V | 33 | 42.3% | 13.6 | NA | NA | ||
| Schneider et al (2007) | Carb–G–Cape | 33 | 39.4% | 7.6 | 35.6% | 14.2% | |
| Greco et al (2008) | Carbo–P–Bv–Er | 51 | 48% | 11.3 | NA | NA |
B=bleomycin; Bv=bevacizumab; Cape=capecitabine; Carbo=carboplatin; Cis=cisplatin; Cy=cyclophosphamide; D=docetaxel; Dx=doxorubicin; E=etoposide; Ep=epirubicin; Er=erlotinib; F=5-FU; G=gemcitabine; I=ifosfamide; Ir=irinotecan; m=months; Mit=mitomycin C; MST=median survival time; NA=not available; Ox=oxaliplatin; P=paclitaxel; RR=response rate; V=vinorelbine.
a
1 year=1-year survival rate.
b
2 year=2-year survival rate.